KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to $8.0 million.

  • Neogenomics' Share-based Compensation fell 343.42% to $8.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $41.3 million, marking a year-over-year increase of 6564.17%. This contributed to the annual value of $41.3 million for FY2025, which is 2365.25% up from last year.
  • Neogenomics' Share-based Compensation amounted to $8.0 million in Q4 2025, which was down 343.42% from $10.3 million recorded in Q3 2025.
  • Neogenomics' 5-year Share-based Compensation high stood at $12.2 million for Q2 2025, and its period low was $2.7 million during Q1 2021.
  • Over the past 5 years, Neogenomics' median Share-based Compensation value was $7.4 million (recorded in 2023), while the average stood at $7.3 million.
  • Per our database at Business Quant, Neogenomics' Share-based Compensation skyrocketed by 35620.05% in 2022 and then plummeted by 6068.74% in 2023.
  • Neogenomics' Share-based Compensation (Quarter) stood at $10.1 million in 2021, then plummeted by 53.66% to $4.7 million in 2022, then soared by 49.9% to $7.0 million in 2023, then rose by 19.14% to $8.3 million in 2024, then dropped by 3.43% to $8.0 million in 2025.
  • Its Share-based Compensation was $8.0 million in Q4 2025, compared to $10.3 million in Q3 2025 and $12.2 million in Q2 2025.